Ozempic and Apixaban Interaction: What Patients and Prescribers Need to Know

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

Is there a direct interaction between semaglutide and apixaban?

Apixaban is an oral direct factor Xa inhibitor [2]. Ozempic is a GLP-1 receptor agonist given once weekly by subcutaneous injection for type 2 diabetes, to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and for kidney outcomes in adults with type 2 diabetes and chronic kidney disease [1].

Apixaban is eliminated by multiple pathways, including renal and non-renal elimination; its non-renal elimination involves CYP3A4 metabolism and direct intestinal excretion [2]. The Ozempic label's drug interactions section covers insulin secretagogues and insulin, and delayed absorption of oral medicines; it does not name apixaban or other anticoagulants [1]. The semaglutide labels describe breakdown by proteolytic cleavage and beta-oxidation rather than by CYP enzymes.

Does slowed gastric emptying change apixaban absorption?

The Ozempic label says the drug causes a delay in gastric emptying and therefore has the potential to affect the absorption of oral medicines given at the same time. The same section states that in clinical pharmacology trials semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree, and that caution should be exercised with oral medicines [1]. The label does not provide apixaban-specific absorption or exposure data.

What apixaban interactions are known?

Apixaban exposure is sensitive to combined P-gp and strong CYP3A4 inhibitors and inducers [2][4]. In 18 healthy subjects, ketoconazole 400 mg daily raised apixaban AUC by 99% and peak concentration by 62%; diltiazem 360 mg daily raised AUC by 40% and peak concentration by 31% [2]. In 20 healthy participants, rifampin 600 mg daily cut oral apixaban AUC by 54% and lowered absolute oral bioavailability from 49% to 39% [4].

The Eliquis label says to cut the dose by 50% when a patient on 5 mg or 10 mg twice daily takes a combined P-gp and strong CYP3A4 inhibitor such as ketoconazole, itraconazole or ritonavir, and to avoid the combination if the patient is already on 2.5 mg twice daily.

In a Belgian cohort of 193,072 people with atrial fibrillation taking a DOAC, P-gp/CYP3A4 inhibitors were associated with more major bleeding (adjusted HR 1.24, 95% CI 1.18 to 1.30) [5]. That cohort looked at interacting drugs, not semaglutide.

Gastrointestinal effects and kidney warnings on Ozempic

In pooled placebo-controlled trials in type 2 diabetes, nausea occurred in 15.8% on 0.5 mg and 20.3% on 1 mg versus 6.1% on placebo, vomiting in 5% and 9.2% versus 2.3%, and diarrhea in 8.5% and 8.8% versus 1.9% [1]. The Ozempic label warns about acute kidney injury from volume depletion and says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation. It recommends no dose adjustment for renal impairment [1]. About 27% of apixaban clearance is renal [2].

Bleeding risk with apixaban

In ARISTOTLE, 18,201 patients with atrial fibrillation received apixaban 5 mg twice daily or warfarin, with median follow-up of 1.8 years. Stroke or systemic embolism occurred at 1.27% versus 1.60% per year (HR 0.79, 95% CI 0.66 to 0.95), and major bleeding at 2.13% versus 3.09% per year (HR 0.69, 95% CI 0.60 to 0.80) [3]. The trial did not test semaglutide with apixaban.

The Eliquis label names aspirin and other antiplatelets, other anticoagulants, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs as drugs affecting hemostasis that add to bleeding risk. GLP-1 receptor agonists are not among the examples it names.

Anesthesia and procedures

The Ozempic label lists pulmonary aspiration during general anesthesia or deep sedation as a warning, reported in patients receiving GLP-1 receptor agonists who underwent elective surgeries or procedures [1]. Separately, the Eliquis boxed warning says epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or spinal puncture and may cause long-term or permanent paralysis.